Abstract: This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.
Type:
Grant
Filed:
August 19, 2016
Date of Patent:
August 20, 2019
Assignee:
The Children's Hospital of Philadelphia
Inventors:
Hakon Hakonarson, Yun Rose Li, Brendan Keating
Abstract: Methods for screening for therapies against autism spectrum disorders and methods for determining whether a subject would be responsive to a therapy against an autism spectrum disorder are disclosed.
Type:
Grant
Filed:
March 17, 2014
Date of Patent:
July 9, 2019
Assignee:
The Children's Hospital of Philadelphia
Inventors:
Timothy P. L. Roberts, James Christopher Edgar
Abstract: Azolylacryloyl derivatives with hypoxic properties are provided. The compounds have a generic formula: and are suitable for treating sickle cell disease and hypoxia-underlying diseases, e.g. hemorrhagic and traumatic shock, cardiac arrest and cardiogenic shock, traumatic brain injury, cancer, stroke, myocardial infarction, myocardial ischemia, vaso-occlusive crisis, etc.
Type:
Grant
Filed:
September 30, 2016
Date of Patent:
July 9, 2019
Assignees:
VIRGINIA COMMONWEALTH UNIVERSITY, KING ABDULAZIZ UNIVERSITY, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Inventors:
Martin K. Safo, Yan Zhang, Mohini Ghatge, Osheiza Abdulmalik, Abdelsattar Mansour Ebid Omar, Moustafa El-Sayed El-Araby
Abstract: Methods and uses of treating a disease in a mammal are provided by administering to a mammalian non-central nervous system (CNS) cell, organ or tissue, for delivery to mammalian CNS (e.g., brain). Methods and uses of treating a disease in a mammal include, inter alia, administering to a mammalian non-ocular cell, organ or tissue for delivery to a mammalian ocular cell, organ or tissue.
Type:
Application
Filed:
September 1, 2017
Publication date:
June 27, 2019
Applicants:
Spark Therapeutics, Inc., The Children's Hospital of Philadelphia
Abstract: Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.
Type:
Grant
Filed:
March 25, 2016
Date of Patent:
June 25, 2019
Assignee:
The Children's Hospital of Philadelphia
Inventors:
John Fraser Wright, Guang Qu, Bernd Hauck, Katherine A. High
Abstract: Devices and methods for securing a catheter and monitoring a catheter insertion site. Exemplary embodiments can allow monitoring of the site without removal of the device. Exemplary embodiments can also secure a catheter while maintaining patient comfort.
Type:
Application
Filed:
May 15, 2017
Publication date:
June 13, 2019
Applicant:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Abstract: Factor VIII variants and methods of use thereof are disclosed. In particular embodiments, Factor VIII variants exhibit one or more improvements compared to wild-type Factor VIII proteins, including wild-type Factor VIII proteins with a B-domain deletion (FVIII-BDD). Examples may include enhanced activity or function, secretion at increased levels by cells or are packaged more efficiently into viral vectors.
Type:
Application
Filed:
January 13, 2017
Publication date:
May 16, 2019
Applicant:
The Children's Hospital of Philadelphia
Abstract: In accordance with the present invention, a method for increasing the yield of rLV vector particles comprising a trans gene encoding a therapeutic protein or fragment thereof is disclosed. In one approach, cells are transfected with plasmids encoding the necessary components for rLV production using a calcium chloride transfection mix at pH 7.1 wherein the calcium chloride and plasmids form a complex which is added to the cells at a constant speed. The cells are then incubated for a suitable time period wherein virus particle media is collected at least twice during the incubation period and stored in a cold storage unit, thereby reducing virus inactivation.
Type:
Application
Filed:
August 27, 2018
Publication date:
March 28, 2019
Applicant:
The Children's Hospital of Philadelphia
Inventors:
Katherine A. High, John Fraser Wright, Bernd Hauck, Guang Qu
Abstract: The present disclosure provides filler or stuffer sequences, compositions thereof including expression cassettes and vectors, such as viral (e.g., AAV) vectors and methods of delivering a therapeutic agent to a mammal and/or treating a disease.
Type:
Application
Filed:
March 17, 2017
Publication date:
March 7, 2019
Applicant:
The Children's Hospital of Philadelphia
Inventors:
Beverly L. DAVIDSON, Alejandro Mas MONTEYS, Megan S. KEISER
Abstract: The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.
Type:
Application
Filed:
September 28, 2018
Publication date:
January 31, 2019
Applicants:
Mezzion Pharma Co., Ltd., The Children's Hospital of Philadelphia, The Children's Hospital of Philadelphia
Inventors:
James L. Yeager, David J. Goldberg, Stephen M. Paridon
Abstract: This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analog thereof.
Type:
Grant
Filed:
March 8, 2017
Date of Patent:
January 29, 2019
Assignees:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, CHILDREN'S HOSPITAL OF PHILADELPHIA
Inventors:
Doris Stoffers, Diva D. De Leon, Charles Stanley
Abstract: This invention relates to a method of diagnosing a subject as having and/or being a carrier for infantile myofibromatosis. This method involves providing an isolated biological sample from a subject; contacting the sample with one or more reagents suitable for detecting the presence or absence of one or more mutations in PDGFRB and/or NOTCH3; detecting, in the sample, the presence or absence of the one or more mutations in PDGFRB and/or NOTCH3 based on said contacting; and diagnosing the subject as having and/or being a carrier for infantile myofibromatosis based on said detecting, where the presence of the one or more mutations in PDGFRB and/or NOTCH3 indicates the subject has a mutation that causes infantile myofibromatosis. Also disclosed is a method of treating a subject having infantile myofibromatosis and a method of preventing or treating symptoms associated with infantile myofibromatosis.
Type:
Grant
Filed:
October 20, 2017
Date of Patent:
December 18, 2018
Assignees:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Inventors:
John A. Martignetti, Hakon Hakonarson, Lifeng Tian
Abstract: The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.
Type:
Grant
Filed:
June 30, 2015
Date of Patent:
November 27, 2018
Assignees:
Mezzion Pharma Co., Ltd., The Children's Hospital of Philadelphia
Inventors:
James L. Yeager, David J. Goldberg, Stephen M. Paridon
Abstract: Compositions and methods for inhibiting, treating, and/or preventing fatty acid metabolism disorders, particularly fatty acid oxidation disorders, in a subject are provided.
Type:
Grant
Filed:
May 9, 2017
Date of Patent:
November 27, 2018
Assignee:
The Children's Hospital of Philadelphia
Inventors:
Harry Ischiropoulos, Paschalis-Thomas Doulias